share_log

Clearmind Medicine | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SEC announcement ·  Feb 23 16:07
Summary by Moomoo AI
Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, has announced the approval to commence a Phase I/IIa clinical trial for its drug candidate CMND-100, aimed at treating Alcohol Use Disorder (AUD). The approval was granted by the Ministry of Health of Israel and was publicized on February 23, 2024. CMND-100 is an oral capsule based on the proprietary molecule MEAI (5-methoxy-2-aminoindane), which is non-hallucinogenic and has shown potential in reducing the desire for alcohol consumption. The clinical trial will assess the tolerability, safety, and pharmacokinetics of CMND-100 in both healthy volunteers and AUD subjects, with a secondary focus on the drug's efficacy in reducing drinking patterns and cravings. The study will be led by Prof...Show More
Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, has announced the approval to commence a Phase I/IIa clinical trial for its drug candidate CMND-100, aimed at treating Alcohol Use Disorder (AUD). The approval was granted by the Ministry of Health of Israel and was publicized on February 23, 2024. CMND-100 is an oral capsule based on the proprietary molecule MEAI (5-methoxy-2-aminoindane), which is non-hallucinogenic and has shown potential in reducing the desire for alcohol consumption. The clinical trial will assess the tolerability, safety, and pharmacokinetics of CMND-100 in both healthy volunteers and AUD subjects, with a secondary focus on the drug's efficacy in reducing drinking patterns and cravings. The study will be led by Prof. Mark Weiser at the Sheba Medical Center in Israel, with additional sites planned in the United States at Yale School of Medicine and Johns Hopkins University School of Medicine. This milestone marks Clearmind's transition to a clinical-stage pharmaceutical company and underscores its commitment to addressing the global challenge of alcoholism. Clearmind's shares are traded on Nasdaq, the Canadian Securities Exchange, and the Frankfurt Stock Exchange under the symbol 'CMND'.

This announcement is a separate document:

Doc 1

Doc 2

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more